Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Production of an Antibody Fragment (Scfv) Targeting Pcrv Protein of Pseudomonas Aeruginosa in Fed-Batch Cultivation Mode Publisher Pubmed



Karam S1, 2 ; Raigani M2 ; Afshar SH1, 2 ; Talebkhan Y2 ; Bayat E2 ; Komijani S2 ; Nematollahi L2 ; Barkhordari F2 ; Ardestani MS3 ; Davami F2
Authors
Show Affiliations
Authors Affiliations
  1. 1. International Campus, School Of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Biotechnology Research Center, Pasteur Institute of Iran, Pasteur Avenue, Tehran, Iran
  3. 3. Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Source: Iranian Biomedical Journal Published:2021


Abstract

Background: Pseudomonas aeruginosa is one of the opportunistic pathogens causing frequent hospital-acquired life-threatening infections in mechanically ventilated patients. The most significant virulence factor of P. aeruginosa is T3SS. PcrV is an important structural protein of the T3SS. Methods: In the current investigation, a recombinant scFv mAb against the PcrV protein was expressed in EnBase® (fed-batch) cultivation mode. The pETiteTM N-His SUMO Kan vector, including anti-PcrV scFv gene, was transformed into Escherichia coli (BL21) cells. The expression and solubility of anti-PcrV scFv protein were investigated at two different temperatures (25 °C and 30 °C) and at different induction times (4, 6, 8, 12, and 24 hours). Results: Increased efficiency was achieved by EnBase® compared to LB broth; owing to the slow release of glucose, the maximum level of solubility and total protein expression was observed in EnBase® cultivation system at 30 °C and 24 h post induction. Furthermore, IC50 for anti-PcrV scFv protein was determined to be approximately 7 μg/mL. Conclusion: Anti-PcrV scFv produced in this study showed promising in vitro results, protecting RBC from lysis by P. aeruginosa (exoU+). © 2021, Pasteur Institute of Iran. All rights reserved.
Related Docs
3. Monoclonal Antibodies for Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
4. The Use of Nanoparticles As a Promising Therapeutic Approach in Cancer Immunotherapy, Artificial Cells# Nanomedicine and Biotechnology (2016)
Experts (# of related papers)